TCL Archive ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial. September 8, 2006
TCL Archive Conversation with The Cancer Letter: Statistician Lori Dodd Saw Research Question In the Midst of 2007 ODAC Debate Over Avastin July 27, 2012